Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 10/2019

01-10-2019 | Tocilizumab | Oculoplastics and Orbit

Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab

Authors: Anna Leszczynska, Blanca Molins, Estrella Fernández, Alfredo Adán, Santiago Ortiz-Perez

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2019

Login to get access

Abstract

Purpose

To compare IL-6, sIL-6R, and IL-17 secretion in peripheral blood mononuclear cells (PBMCs) cultured with tocilizumab (a humanized monoclonal antibody against the interleukin-6 receptor), dexamethasone, and placebo, obtained from patients with thyroid eye disease (TED) and healthy controls.

Methods

The study was a prospective proof of concept test. We cultured peripheral blood mononuclear cells from TED patients and healthy controls with tocilizumab, dexamethasone, and placebo. IL-6, sIL-6R, and IL-17 levels in supernatants obtained from PBMCs cultures were analyzed by ELISA.

Results

We included seventeen patients with thyroid eye disease (12 females and five males). The mean age was 49 years. Both dexamethasone and tocilizumab influenced IL-6 and IL-6Rs levels in patients’ group. Supernatants obtained from PBMCs treated with dexamethasone showed 77.2% and 82.8% lower IL-6 levels compared with those cultured with placebo and tocilizumab, respectively. Furthermore, overnight culture of PBMCs with dexamethasone showed significantly lower sIL-6R secretion compared with untreated (33.71%, p = 0.04) and tocilizumab treated (58.21%, p = 0.01) PBMCs. Neither dexamethasone nor tocilizumab affected IL-17 concentrations in PBMCs cultures.

Conclusions

Both dexamethasone and tocilizumab affect the IL-6/sIL-6R system. Specifically, dexamethasone reduces and tocilizumab increases the levels of these cytokines in PBMCs cultures. These results strengthen the molecular rationale for interrogating the efficacy of tocilizumab in steroid-resistant TED, as IL-6 seems to be a common target for both anti-IL-6R antibody and steroids.
Literature
1.
2.
Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90:5234–5240CrossRefPubMed
3.
4.
5.
Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF (2003) TSH-R expression and cytokine role in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol 58:280–287CrossRef
6.
Xia N, Zhou S, Liang Y, Xiao C, Shen H, Pan H, Deng H, Wang N, Li QQ (2006) CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves’ ophthalmopathy. Int J Mol Med 17:911–916PubMed
7.
Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE, Roti E (1996) Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves’ disease. J Clin Endocrinol Metab 81:2976–2979PubMed
8.
Maini RN, Taylor PC, Szechinski, CHARISMA Study Group et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829CrossRefPubMed
9.
Pérez-Moreiras JV, Alvarez-López A, Gómez EC (2014) Treatment of active corticosteroid-resistant Graves’ orbitopathy. Ophthal Plast Reconstr Surg 30:162–167CrossRefPubMed
10.
Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Tocilizumab in Graves Orbitopathy Study Group et al (2018) Efficacy of tocilizumab in patients with moderate to severe corticosteroid resistant Graves’ orbitopathy: a randomized clinical trial. Am J Ophthalmol 195:181–190CrossRefPubMed
11.
Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R (1989) Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 73(8):639–644CrossRefPubMedPubMedCentral
12.
Rincon M (2012) Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 33:571–577CrossRefPubMed
13.
14.
15.
Chen B, Tsui S, Smith TJ (2005) IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol 175:1310–1319CrossRefPubMed
16.
Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A et al (2012) CD8 + CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves’ orbitopathy and correlate with disease activity. Endocr Res 37:89–95CrossRefPubMed
17.
Kim SE, Yoon JS, Kim KH, Lee SY (2012) Increased serum IL-17 in Graves’ ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 250(10):1521–1526CrossRefPubMed
18.
19.
Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8:1237–1247CrossRefPubMedPubMedCentral
20.
Verhoog NJ, Du Toit A, Avenant C, Hapgood JP (2011) Glucocorticoid-independent repression of tumor necrosis factor (TNF) α-stimulated interleukin (IL)-6 expression by the glucocorticoid receptor. J Biol Chem 286:19297–19310CrossRefPubMedPubMedCentral
21.
22.
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 112:3959–3964CrossRefPubMed
23.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441:235–238CrossRefPubMed
24.
Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179–189CrossRefPubMed
25.
Mills KH (2008) Induction, function and regulation of IL-17- producing T cells. Eur J Immunol 38:2636–2649CrossRefPubMed
26.
27.
Carbone G, Wilson A, Diehl SA, Bunn J, Cooper S, Rincon M (2013) Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci 9:279–288CrossRefPubMedPubMedCentral
Metadata
Title
Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab
Authors
Anna Leszczynska
Blanca Molins
Estrella Fernández
Alfredo Adán
Santiago Ortiz-Perez
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2019
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-019-04419-7

Other articles of this Issue 10/2019

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2019 Go to the issue

Inflammatory Disorders

Predictive value of positive temporal artery biopsies in patients with clinically suspected giant cell arteritis considering temporal artery ultrasound findings

Retinal Disorders

Results of lamellar macular hole-associated epiretinal proliferation embedding technique for the treatment of degenerative lamellar macular hole

Cataract

Incidence and risk factors for retinal detachment after cataract surgery in Korea: a nationwide population-based study from 2011 to 2015

Cornea

Postoperative pain following Descemet membrane endothelial keratoplasty (DMEK): a prospective study

Retinal Disorders

Evaluation of lamina cribrosa thickness in patients diagnosed with central retinal vein occlusion

Glaucoma

Ab interno tube ligation for refractory hypotony following non-valved glaucoma drainage device implantation